This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer (PROTAXY)

This study has been completed.
Information provided by (Responsible Party):
Philippe Chollet, Centre Jean Perrin Identifier:
First received: November 10, 2009
Last updated: April 9, 2013
Last verified: November 2009
RATIONALE : Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary supplements, such as phytochemicals, may stop or delay the development of prostate cancer.

Condition Intervention Phase
Metastatic Prostate Cancer Dietary Supplement: phytochemical Drug: Docetaxel Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First Line Treatment of Hormone Independent Metastatic Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Philippe Chollet, Centre Jean Perrin:

Primary Outcome Measures:
  • Response rate as assessed by clinical, biological and paraclinical examination

Secondary Outcome Measures:
  • Safety as assessed by NCI CTCAE v3.0
  • To assess the best neuroendocine markers between chromogranin A (CgA), neuron-specific enolase (NSE) and serotonin
  • Time to progression as assessed by RECIST criteria and PSA level
  • To assess compliance of per os phytonutrient treatment
  • Geriatric assessment impact on compliance

Enrollment: 30
Study Start Date: September 2009
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of this study is to assess the pathological response rate in metastatic prostate cancer patients treated by : Docetaxel with a phytochemical

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >18
  • WHO performance status 0-2
  • Life expectancy ≥ 3 months
  • Patients receiving androgen-suppressive therapy in the form of chirurgical castration by orchiectomy or pulpectomy,or medical by LHRH agonist or antagonist with or without anti-androgen or all treatment blocking non gonadic testosterone fraction
  • Resulting to testosteronemia <0,5 ng/ml
  • Histologically confirmed adenocarcinomia of prostate cancer and documented hormone independant metastatic disease - defined by: objective progression with at least one measurable lesion and/or evaluable lesion according to RECIST criteria and /or a rise in PSA level ("rising PSA")
  • Total bilirubin ≤ upper limit of normal (ULN).
  • AST and ALT ≤ 1.5 times ULN. Alkaline phosphatase ≤ 2.5 times ULN.
  • Serum creatinine < 140 µmol/L or creatinine clearance > 60 mL/ min.
  • Neutrophil count > 2.109 L-1.
  • Platelet count ≥ 100,000/mm3.
  • Hemoglobin ≥ 10 g/dL
  • Not previous chemotherapy, except Estracyt
  • No liver, kidney or heart failure link to treatment
  • No malabsorption syndrome or disease significantly affecting gastrointestinal function
  • Prior radiotherapies are permetted withing four weeks of the first study treatment and must be < 25 % of the bone marrow, and all adverse events must be resolved
  • Prior surgery are permitted.

Exclusion Criteria:

  • Age < 18
  • History of psychiatric disorders including psychotic disorder, dementia or seizures that would prohibit the understanding, observance and giving of informed consent
  • Previous or concomitant other malignancies except basal or squamous cell carcinoma of the skin or other cancer curatively treated with surgery and/or radiotherapy
  • Patients should not have symptomatic brain metastasis
  • Concurrent severe and/or uncontrolled co-morbid medical condition
  • Malabsorption syndrome or disease significantly affecting gastro-intestinal function or major resection of the stomach, proximal small bowel or grade > 2 dysphagia
  • Patients with uncontrolled infection
  • History of significant neurologic (i.e. peripheral neuropathy grade > 2 using NCI-CTC criteria v3.0)
  • Patients should not have received NSAIDs or COX2 inhibitors within the three weeks prior to starting the study
  • Treatment with any investigational drug within 30 days prior to registration
  • Patients should not have current regimen containing dietary phytonutrients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01012141

Centre Jean Perrin
Clermont-Ferrand, France, 63011
Institut Jean Godinot
Reims, France, 51056
Sponsors and Collaborators
Centre Jean Perrin
Study Chair: Philippe Chollet, MD Centre Jean Perrin
  More Information

Responsible Party: Philippe Chollet, Pr, Centre Jean Perrin Identifier: NCT01012141     History of Changes
Other Study ID Numbers: AU 793
Study First Received: November 10, 2009
Last Updated: April 9, 2013

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017